Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valneva ( (VALN) ) has issued an update.
On April 29, 2026, Valneva SE agreed a €37 million private placement of 15,893,817 new ordinary shares, each bundled with a warrant, at €2.33 per unit, with closing expected on May 5, 2026. If all attached warrants, exercisable at €2.96 until up to September 30, 2028 depending on U.S. FDA approval of its Lyme disease vaccine candidate, are exercised, the company could raise a further approximately €47 million.
The company plans to use the proceeds, together with existing cash, to advance its vaccine pipeline, support growth of its commercial vaccine franchise, and for general corporate purposes, signalling a bid to strengthen its balance sheet ahead of key regulatory milestones. Valneva also signed a registration rights agreement requiring it to register the new shares and warrant shares for resale within defined SEC timelines, with liquidated damages payable to investors if it misses filing or effectiveness deadlines, underscoring investor protections in the transaction.
The most recent analyst rating on (VALN) stock is a Sell with a $4.90 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative free cash flow, and elevated leverage) and bearish technical momentum (price below major moving averages with negative MACD). The latest earnings call adds some support via liquidity/cash-burn improvement and pipeline catalysts, but guidance implies a 2026 revenue step-down and key upside (Lyme) remains timing-dependent. Valuation is difficult to assess with a negative P/E and no dividend yield provided.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a French specialty vaccine company that develops and commercializes prophylactic vaccines, with a pipeline that includes a 6‑valent OspA‑based Lyme disease vaccine candidate (LB6V, formerly VLA15). The group focuses on differentiated vaccines targeting infectious diseases and runs a cash‑generating commercial vaccines business alongside its R&D programs.
Average Trading Volume: 86,465
Technical Sentiment Signal: Strong Sell
Current Market Cap: $467.6M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.